Chest pain, sudden shortness of breath, swelling or pain in one leg, sudden weakness, or trouble speaking needs emergency care; any bleeding after menopause should be checked promptly.
Menopause itself is a single point in time, the final menstrual period, and almost everything people describe as menopause happens in the years of hormonal change around it. This guide explains the therapy at the level of the class, how clinicians think about who may be a candidate, why timing keeps coming up, and what happens in an evaluation before anything is prescribed.
At the level of the class, menopausal hormone therapy is estrogen-based therapy, given together with a progestogen when the uterus is still present, used to manage symptoms that follow the fall in ovarian hormone production 1. That is the whole architecture. Everything else, the form, the strength, the schedule, is a clinical decision made for one person by a licensed provider after an evaluation.
The reason a single hormonal change produces such a scattered list of complaints is that estrogen receptors sit in a lot of different tissue. The part of the brain that regulates body temperature is sensitive to estrogen, which is why hot flashes and night sweats appear. Vaginal and lower urinary tissue is estrogen-dependent, which is why dryness, irritation and discomfort with sex show up. Bone remodelling shifts after menopause. Sleep, mood and concentration often change alongside the rest, sometimes directly and sometimes because broken sleep makes everything else worse.
Hormone therapy works by restoring part of that signalling, not by restarting the ovaries. It does not reverse menopause, and it does not stop ageing. A contemporary review of menopausal hormone therapy describes it as one option within a broader menopause care plan rather than an automatic step for everyone passing through the transition 3.
No article can tell you which form or strength fits your body. That judgement belongs to a provider who has your history in front of them.
A progestogen is added because estrogen given on its own stimulates the lining of the uterus, and progestogen exposure is what protects that lining in combined therapy 2. This is the single most consistent structural rule in the whole category.
A systematic review of progestogens used for endometrial protection in combined menopausal hormone therapy indicates that the choice of progestogen and the adequacy of exposure are central to that protective effect 2. In other words, the progestogen is not an optional extra or a secondary ingredient. It is the reason combined therapy exists as a separate category from estrogen-alone therapy.
People who have had a hysterectomy do not have an endometrium to protect, and estrogen-alone regimens are the usual approach in that situation 1. That is a decision a provider confirms from surgical history, not something to assume.
Two practical points follow. First, bleeding patterns on combined therapy vary by regimen, and unscheduled or persistent bleeding is something to report to the prescriber rather than wait out. Second, any bleeding after menopause, on therapy or off it, is worth discussing with a clinician promptly so the cause can be identified. Local vaginal therapy is handled differently, because systemic absorption from those forms is generally low, and endometrial protection is approached accordingly 1.
The difference is reach. Systemic forms circulate through the body and are used when symptoms are body-wide, while local vaginal forms act mainly on vaginal and nearby tissue with limited systemic absorption 1.
| Feature | Systemic forms | Local vaginal forms |
|---|---|---|
| Where it acts | Whole body through the circulation | Vaginal and surrounding tissue, with limited systemic absorption 1 |
| Symptoms usually targeted | Hot flashes, night sweats, sleep disruption, bone loss prevention 1 | Vaginal dryness, irritation, discomfort with sex, some urinary symptoms 1 |
| Progestogen when the uterus is present | Generally part of the regimen 2 | Usually handled differently because absorption is low; the provider confirms 1 |
| Delivery routes available | Oral and non-oral routes, which differ in how the hormone enters circulation 4 | Applied directly to the tissue |
| Who decides form and strength | A licensed provider after evaluation | A licensed provider after evaluation |
A person whose only real complaint is vaginal dryness and painful sex is in a different conversation from a person waking five times a night drenched. Research suggests that local vaginal therapy is the usual starting point when genitourinary symptoms are the main problem, while systemic therapy is considered when vasomotor symptoms dominate 1. Some people end up using both, and that combination is a provider decision.
The clearest use is vasomotor symptoms. Research suggests that systemic hormone therapy is the most effective available option for hot flashes and night sweats in appropriately selected people 1.
The second clear use is the genitourinary syndrome of menopause, the cluster of vaginal dryness, irritation, discomfort with sex and some urinary symptoms. These symptoms differ from hot flashes in one important way. Hot flashes usually fade over years. Genitourinary symptoms tend to persist or progress without ongoing care, which changes how duration is discussed.
Bone is the third area. Systemic hormone therapy is associated with reduced bone loss and fewer fractures in postmenopausal women, which is why skeletal risk is part of the discussion for some candidates 1.
Sleep and mood are more mixed. Many people sleep better once night sweats settle, and that knock-on effect is real, but hormone therapy is not a general-purpose answer for low mood, anxiety or cognitive complaints, and those deserve their own assessment. The 2022 position statement from The North American Menopause Society frames the decision around bothersome symptoms and individual risk rather than around menopausal status alone 1.
The short version is that candidacy is usually framed around bothersome symptoms, age under 60 or within 10 years of menopause onset, and the absence of specific contraindications 1. Everything in the table below is a starting frame for a conversation, not a verdict on any individual.
| Situation | How it is generally viewed |
|---|---|
| Bothersome hot flashes, under 60 or within 10 years of menopause onset, no contraindications | Often a candidate, with a benefit-risk balance that major guidance describes as favourable in this group 1 |
| Vaginal and urinary symptoms only | Local vaginal therapy is commonly considered first 1 |
| Personal history of venous thromboembolism or stroke | Generally not a candidate for systemic therapy without specialist input 1 |
| History of breast cancer or another hormone-sensitive cancer | Generally considered a contraindication, with oncology input required 1 |
| Active liver disease | Generally considered a contraindication to systemic therapy |
| Unexplained vaginal bleeding | Needs evaluation before therapy is considered 1 |
| Premature or early menopause | Therapy is often considered at least until the usual age of natural menopause 1 |
| Known high cardiovascular risk | Individual assessment, with timing and route weighed carefully |
A family history of breast cancer, a history of migraine with aura, high blood pressure, gallbladder disease, smoking and obesity all enter the calculation without automatically closing the door. This is exactly why the decision cannot be made from a web page. A licensed provider evaluates whether any form of hormone therapy is appropriate for a specific person.
Timing matters because the same therapy carries a different balance of benefit and risk depending on age and how long ago menopause happened. Research suggests that initiating therapy closer to menopause onset, in women under 60 or within 10 years of their final period, is associated with a more favourable benefit-risk profile than initiating it many years later 5.
This is also why the public conversation about hormone therapy has shifted so much. Early reporting from large trials was generalised to all women at all ages, and later analysis separated the picture by age group and time since menopause 3. A contemporary review describes this re-evaluation as a central reason clinicians now individualise the decision rather than apply one rule to everyone 3.
For a reader, the practical takeaway is simple. If symptoms are bothersome, the conversation is worth having sooner rather than filing it away for a few years, because the window being discussed in the guidance is defined partly by the calendar. The decision still belongs to a provider after an evaluation.
Yes, route matters, and it is one of the main levers a provider has. Oral systemic estrogen passes through the liver first, which affects clotting factors, while non-oral routes bypass that first pass, and studies indicate that non-oral routes are associated with a lower risk of venous thromboembolism than oral routes 4.
That single difference explains a lot of prescribing behaviour. For someone with a higher baseline clotting risk, the route choice may be the difference between therapy being considered at all and being ruled out. A contemporary review of menopausal hormone therapy describes formulation and route as part of tailoring the regimen to the individual rather than interchangeable details 3.
The same logic applies in reverse for local vaginal therapy. Because systemic exposure from these forms is low, they are generally viewed differently from systemic therapy in people whose main concern is vaginal and urinary symptoms 1.
Two things are deliberately absent from this article. There are no product names, and there is no strength or schedule information for any form. Those are decisions made by a licensed provider who knows your history, your blood pressure, your screening status and your preferences. Anyone offering a specific regimen before an evaluation has skipped the step that matters.
A provider weighs clotting risk, stroke risk, breast tissue risk, endometrial protection and cardiovascular context, and each is assessed against the individual rather than against the category as a whole. An umbrella review of menopausal hormone therapy and women's health mapped both benefits and harms across a wide set of outcomes and found that the direction and size of associations differ by outcome, regimen and population 6.
Venous thromboembolism is the risk most directly influenced by route, as described above 4. Stroke risk is weighed alongside age, blood pressure and vascular history. Breast cancer risk is handled differently for estrogen-alone and combined regimens and is also influenced by duration, which is one reason the discussion is revisited over time rather than settled once 1. Endometrial risk is addressed by adequate progestogen exposure in people with a uterus 2.
Two framing points keep these numbers in perspective. First, for most healthy people who start near menopause onset, the absolute risks described in current guidance are small, and guidance presents them that way rather than as a blanket warning 1. Second, risk is not static. It changes with age, weight, blood pressure, smoking status and new diagnoses, so a therapy that fitted well at 51 is reassessed at 58.
None of this is a reason to self-assess. It is the reason the evaluation exists.
There is no fixed stopping date set by the calendar alone, and current guidance moved away from arbitrary duration limits toward periodic, individualised reassessment 1. Duration is revisited as age, symptoms and health history change.
In practice, three patterns come up. Some people use systemic therapy for a few years while vasomotor symptoms are at their worst and then taper off with their prescriber. Some continue longer because symptoms return promptly when therapy stops, and the benefit-risk conversation still favours continuing. Some use local vaginal therapy on an ongoing basis, because genitourinary symptoms do not usually resolve on their own, and guidance treats that situation separately from systemic therapy 1.
People with premature or early menopause sit in a different category again. Guidance generally supports therapy at least until the usual age of natural menopause in that group, because the comparison is with normal hormonal exposure for that age rather than with no exposure 1.
Stopping is also a clinical decision. Whether to taper or stop abruptly, and what to expect afterwards, is something to plan with the prescriber rather than decide alone. A review of menopausal hormone therapy framed around for whom, what, when and how long describes duration as part of a continuing shared decision rather than a one-time choice 5.
An evaluation is mostly history and conversation, with targeted measurements where they change the decision. Current guidance describes the process as shared decision making between patient and clinician, with reassessment over time 1.
Expect questions about the pattern and severity of symptoms, the date of the last menstrual period, any bleeding since then, surgical history including hysterectomy, personal history of clots, stroke, heart disease, liver disease and cancer, family history of breast and ovarian cancer, migraine pattern, smoking, and current medicines. Expect blood pressure to be measured and screening status, including mammography and cervical screening, to be checked and brought up to date.
The conversation then moves to preferences. Some people care most about sleep, some about sexual comfort, some about bone protection, and the priority shapes which form is discussed. The provider explains what is known about benefits and risks for someone with that specific profile, and the decision is made together.
Atlas, FitScript's AI health advisor, interprets member results from the 150+ biomarkers tested per year and prepares that context for review, while any decision to start, stop or change a prescription therapy is made by a licensed provider after an evaluation. Testing adds context to a decision. It does not make the decision.
No. In people over about 45 with typical symptoms, the decision is driven by symptoms, age, time since the last period and personal history, not by a single hormone value. Hormone levels in perimenopause swing from week to week, so one reading can mislead in either direction.
Markers still earn their place in specific situations. FSH is the one most often ordered, because it rises as ovarian function declines, and it is more useful when the clinical picture is unclear, for example in someone under 45 with absent periods, after a hysterectomy where cycle tracking is impossible, or when another cause of symptoms is being ruled out. Even then it is interpreted as part of a pattern rather than as a switch.
The honest framing is observation, meaning, next step. The observation is a number on a page. The meaning is a hypothesis about where someone sits in the transition. The next step is a conversation with a clinician who can combine that with symptoms, history and examination. A result that sits outside a standard reference range is worth discussing with a clinician rather than acted on alone, and a result inside the range does not rule out bothersome symptoms that deserve care.
The markers worth checking are mostly the ones that explain overlapping symptoms or inform the risk side of the decision. None of them diagnose menopause, and none of them replace a clinical assessment.
Thyroid markers come first, because fatigue, temperature intolerance, mood change, hair thinning and cycle change overlap heavily with the menopause transition and can come from the thyroid instead, or as well. A complete blood count and ferritin matter for anyone with heavy or prolonged perimenopausal bleeding, where iron depletion is a common and fixable driver of exhaustion.
On the risk side, a lipid panel, a fasting glucose or HbA1c, liver enzymes, kidney function and blood pressure give the cardiometabolic context a provider weighs when discussing route and timing. Vitamin D and, where indicated, bone density assessment inform the skeletal part of the conversation.
Estradiol, LH, testosterone and SHBG are sometimes added when the clinical picture is unusual or when sexual symptoms are prominent. They are interpretive, not decisive. Tracking symptoms in writing for a few weeks, including frequency of hot flashes, sleep interruptions and their effect on daily function, often changes a consultation more than any single blood result does.
Plenty of people are not candidates, and plenty of candidates simply prefer not to take it. That is a legitimate position, and it does not mean doing nothing.
Non-hormonal prescription options exist for vasomotor symptoms, and a 2025 narrative review of menopausal hormone therapy describes both established alternatives and emerging options being developed for symptom management 7. Whether any of them is appropriate is a question for a licensed provider, and this guide deliberately names none of them.
Outside prescriptions, the levers are unglamorous and worth using. Resistance training supports muscle mass and bone loading through a period when both are under pressure. Protein intake often needs attention as appetite and body composition shift. Sleep timing, caffeine and alcohol frequently influence how severe night sweats feel. Layered clothing, a cooler bedroom and managing stress load change day-to-day tolerability. Pelvic floor physiotherapy helps some people with urinary symptoms. Non-hormonal vaginal moisturisers and lubricants address comfort during sex for many, independently of any prescription.
The realistic expectation is that these measures reduce burden rather than eliminate symptoms. If symptoms are still interfering with sleep, work or relationships after a fair chance, that is a reason to revisit the prescription conversation with a clinician rather than to accept the situation.
Sexual symptoms at menopause usually split into two separate problems, and they are managed differently. Physical comfort, meaning dryness, irritation and pain with sex, falls under the genitourinary syndrome of menopause, for which local vaginal therapy is commonly the first option considered 1.
Desire is a different question. It responds to sleep quality, mood, relationship context, body image, pelvic pain, medicines being taken for other conditions and general energy, not to one hormone alone. Fixing comfort sometimes restores desire on its own, because pain is a powerful suppressant, and sometimes it does not, which is why a provider will often ask about all of those domains before concluding anything.
The ordering matters in practice. Addressing pain first tends to make the rest of the assessment clearer, because it removes the most obvious confounder. When desire remains low after comfort improves, the assessment usually widens to sleep, thyroid function, iron status, mood and relationship factors.
This is also an area where people wait far too long to raise the subject, often years. Clinicians who work in menopause care expect the question, and raising it early shortens the path to something that helps.
It is time when symptoms are affecting sleep, work, mood or relationships, when periods change in a way that worries you, or when you simply want the benefit-risk conversation for your own situation rather than the population average. There is no threshold of suffering you have to reach first.
Some situations deserve prompt attention rather than a routine appointment. Any vaginal bleeding after menopause should be checked promptly. Bleeding that is unusually heavy, prolonged or frequent during perimenopause should also be assessed. New severe headaches, a new breast lump, or symptoms that change character suddenly are all reasons to get in touch sooner.
And the emergency list stands on its own. Chest pain, sudden breathlessness, swelling or pain in one leg, sudden weakness on one side, or trouble speaking means emergency care, not an appointment next week.
This article is educational and is not medical advice. Discuss your symptoms, your results and any decision to start, stop or change hormone therapy with a clinician or licensed provider who can evaluate your full history.
If you want to go deeper on how clinicians approach the hormonal side of women's health across the transition, the overview of hormone care for women covers the wider picture, and if sexual symptoms are the main thing on your mind, the guide to libido for menopause goes further into comfort, desire and what tends to be assessed first.
No. It is one option among several, and whether it fits depends on your symptoms, your age, how long ago your last period was, and your personal and family history. A licensed provider evaluates all of that before deciding whether any form is appropriate for you.
Usually the decision rests on symptoms, age and history rather than on a hormone level, because hormone values swing widely during the transition. Testing is more useful when the picture is unclear, for example in someone under 45 or after a hysterectomy, or when another cause of symptoms is being ruled out. Your provider decides what is worth measuring.
It is still a conversation worth having, but the balance of benefits and risks is weighed differently the further you are from your final period. A provider will look at your age, time since menopause, vascular health and symptom burden before advising. Starting later is not simply a delayed version of starting earlier.
There is no fixed end date set by the calendar. Duration is individualised and reassessed periodically as your age, symptoms and health history change. Some people use it for a few years, some continue longer, and local vaginal therapy is often approached differently from systemic therapy.
Local vaginal therapy is commonly the first option discussed when those symptoms are the main concern, and non-hormonal moisturisers and lubricants help many people with comfort. Because these symptoms tend to persist rather than fade on their own, they are usually managed on an ongoing basis. A provider confirms what suits your situation.
Talk to your prescriber first. Whether to taper or stop outright, and what to expect afterwards, depends on the form you are using and how long you have been on it. Planning the stop with a clinician avoids surprises and gives you a clear next step if symptoms return.
Any bleeding after menopause should be checked promptly, whether or not you are on therapy. It has several possible causes, and the point of the appointment is to identify which one applies. Do not wait to see if it happens again.
Non-hormonal prescription options exist and are something to ask a licensed provider about. Alongside those, resistance training, sleep timing, caffeine and alcohol adjustments, a cooler sleeping environment, pelvic floor physiotherapy and non-hormonal vaginal products all reduce symptom burden for many people. If symptoms still interfere with daily life after a fair chance, go back to your clinician rather than accept it.